Analysis of Tumor Marker CA 125 in Saliva of Normal and Oral Squamous Cell Carcinoma Patients: A Comparative Study
Jude J Balan, BR Premalatha
Citation Information :
Balan JJ, Premalatha B. Analysis of Tumor Marker CA 125 in Saliva of Normal and Oral Squamous Cell Carcinoma Patients: A Comparative Study. J Contemp Dent Pract 2012; 13 (5):671-675.
The mortality and morbidity associated with oral squamous cell carcinoma (OSCC) can be greatly reduced if tumor markers which can detect OSCC at an early stage are available. The use of saliva as an alternative to blood could provide a substantial advantage in sampling convenience. Cancer antigen 125 (CA 125) is a tumor-associated antigen found to be increased in epithelial tumors like oral, breast and ovarian cancers.
Aim
To determine whether salivary CA 125 levels are increased significantly in OSCC patients than the control group.
Materials and methods
Sixty OSCC patients and 60 healthy controls were taken for the study. Saliva samples from both the groups were collected, centrifuged and supernatant fluid were subjected to ELISA for assessment of CA 125. The mean salivary CA 125 values of OSCC patients and control group were statistically analyzed using Mann-Whitney U-test.
Results
The mean salivary CA 125 concentration of OSCC group was 320.25 and that of control group was 33.14. Thus, CA 125 was found to be significantly increased in the saliva of OSCC patients than the control group (p < 0.001). Also, there was significant increase in the CA 125 levels as the stage of OSCC increased.
Conclusion
The convenience, reliability and noninvasive nature of salivary CA 125 testing makes it a feasible adjunctive diagnostic tool for detection of OSCC.
How to cite this article
Balan JJ, Rao RS, Premalatha BR, Patil S. Analysis of Tumor Marker CA 125 in Saliva of Normal and Oral Squamous Cell Carcinoma Patients: A Comparative Study. J Contemp Dent Pract 2012;13(5):671-675.
Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
Focus on molecules: Human mucin MUC16. Exp Eye Res 2008;87(5):400-401.
New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15(Suppl 3):274-81.
Survival following primary surgery for oral cancer. Oral Oncol 2009;45:201-11.
Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay? Oral Dis 2010;16:333-42.
Evaluation of screening strategies for improving oral cancer mortality: A cochrane systematic review. J Dent Educ 2005;69:255-65.
Effect of screening on oral cancer mortality in Kerala, India: A cluster randomized controlled trial. Lancet 2005;365:1927-33.
Application of saliva for drug monitoring: An in vivo model for transmembrane transport. Eur J Clin Biochem 1996;34:171-91.
Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992;23:365-79.
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012 Feb 16;31(7):805-17.
Downregulation of cell surface CA 125/MUC16 induces epithelial-tomesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011;104:989-99.
Concomitant analysis of salivary tumor markers. A new diagnostic tool for oral cancer. Clin Cancer Res 2006;12(13):3979-84.
Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol. Biomarkers Prev 2007;16(1):102-07.
Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990 Apr;75(4):701-04.
Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer. Obstet Gynecol 1993 Jun;81(6):989-92.
Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009 Nov 1;10(6):E001-08.
Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore 1994 May;23(3):311-14.
The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990;163:1164-67.
